Varian and Icon Group partner to extend commitment to global cancer care

29 Apr 2021
Edward Carter
Publishing / Media

Industry news

Varian, a Siemens Healthineers company, has signed an agreement with Australia’s Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing global cancer burden. This agreement further strengthens the global partnership between Varian and Icon Group, together with increasing access to care across regional and underserviced areas in Australia and Asia.

The order is comprised of a variety of Varian linear accelerators and software including Halcyon™, TrueBeam®, and HyperArc™. These systems will be installed in new and existing Icon cancer centers in Australia to increase capacity and broaden patient access, as well as in cancer centers in Singapore and China.

“We are extremely proud of our global partnership with Varian, which continues to help meet our long-term goal of increasing access to care. This investment helps to address the cancer burden in rural and regional Australia and underserved communities in Singapore and China,” said Mark Middleton, CEO of Icon Group. “It’s great to see progress being made on the path to a world where cancer is no longer a burden; where people have every opportunity to fight cancer no matter where they live.”

Icon continues to play a paramount role in the development of radiation oncology treatments and has been an early adopter of Varian technologies over the years, including the first in Australasia to install the Varian Halcyon radiotherapy system and first in Australia to install and treat with HyperArc technology – benefitting patients with multiple tumors in the brain. Icon Group is also a member of the Varian Adaptive Intelligence™ Consortium, alongside other international institutions, to collaboratively develop clinical and technical aspects of Ethos™ therapy and wider radiation therapy treatments and techniques that will continue to evolve cancer care.

“We are honored to be selected once again by Icon Group to provide Varian radiotherapy and radiosurgery systems for its cancer centers around the world,” said Chris Toth, CEO, Varian, a Siemens Healthineers company. “As the cancer burden continues to rise, we are proud to work with our global partners at Icon Group to expand access to advanced cancer care to achieve a world without fear of cancer.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags

Cell Lines Stem Cells and Primary CellsPrimary cell cultures, established cell lines and stem cells are vital for <i>in vitro</i> and <i>ex vivo</i> experimentation. High-quality cells, optimized for your applications, alongside optimized cell substrates, growth medium and supplements, are critical for experimental success. Explore a range of cells suitable for your applications, including isogenic cell lines, competent cells, induced pluripotent stem cell (iPSC)-derived cell lines, fungal/bacterial/mammalian cell lines, stem cells and cancer cell lines. Find the best cells for your research in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.ChemotherapyCancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.